Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Is it possible to reach an operational cure for CML?

Giuseppe Saglio • 9 Jun 2016
EHA 2016
Chronic Myeloid Leukemia

Giuseppe Saglio, MD from University of Turin, Turin, Italy discusses the influence of tyrosine kinase inhibitor (TKI) therapy on the treatment of chronic myeloid leukemia (CML). Over the past few years it has been shown that patients can achieve a status called operational cure, where it is possible for them to stop therapy – however, the number of patients holding this status is low. Prof Saglio holds hope that in the future this number will rise and mentions the potential of using a stronger TK inhibitor to increase the number of patients holding an operational cure. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

More from Giuseppe Saglio

Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
1:04
Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
Giuseppe Saglio • 5 Mar 2025
Factors affecting adherence to TKI therapy in patients with CML
1:52
Factors affecting adherence to TKI therapy in patients with CML
Giuseppe Saglio • 5 Mar 2025
The use of asciminib in the frontline treatment of CML
4:12
The use of asciminib in the frontline treatment of CML
Giuseppe Saglio • 5 Mar 2025
Commonly observed side effects with asciminib and how to manage them
1:29
Commonly observed side effects with asciminib and how to manage them
Giuseppe Saglio • 5 Mar 2025

Related Videos

Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
Beyond the label: optimal dosing strategies for CML in community practice
0:51
Beyond the label: optimal dosing strategies for CML in community practice
Fadi Haddad • 10 Sep 2026
Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Optimizing frontline therapy selection to prevent resistance in CML
1:58
Optimizing frontline therapy selection to prevent resistance in CML
Jorge Cortes • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals